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1. Introduction
A statistical analysis of the number of new U.S. Food and Drug
Administration (FDA) approvals in the period between 1969
and 2016 had shown a downward trend from its highest point
in 1996 (53 new molecular entities (NMEs)/year) and the mini-
mum after 1996 of 15 NMEs/year in 2010 and 2016 [1].
However, 2017 and 2018 appear to be turning years in devel-
opment pipelines with higher NMEs/year values (34 and 52,
respectively), almost surpassing even the highest NMEs value
(53 NMEs/1996) in 2018 [2]. The global marine pharmaceutical
clinical pipeline comprising 30 compounds, which includes
eight approved drugs by the most representative approving
agencies such as U.S. FDA, European Medicines Agency
(EMEA), Japanese Ministry of Health and Australia’s
Therapeutic Goods Administration, Figure 1, and 22 drug can-
didates in phase III, II, or I of drug development [1,3–5].
Interestingly, more than half of the total approvals of marine
natural products (MNPs) and derivatives occurred in the 21st
century (six out of eight approved drugs) [1], Figure 1. Figure 1
also highlighted the year and the approval agency for the first
approval of the eight approved drugs of marine origin. In
clinical trials phase III, there are six MNPs and derivatives,
which includes four small molecules and two antibody-drug
conjugates. In Figure 2(a), the chemical structures of the four
small molecules in phase III were represented, which includes
three anti-cancer compounds (plinabulin, lurbinectedin, and
salinosporamide A) and one analgesic compound (tetrodo-
toxin) [6,7]. While in phase II there are 10 MNPs and deriva-
tives, from those three are small molecules, one anti-cancer
compound (plocabulin) and two are active against Alzheimer’s
disease (DMXBA and bryostatin) according to pre-clinical stu-
dies that were previously performed, Figure 2(b). All the MNPs
and derivatives in phase I of the clinical trials are formerly
established as anti-cancer antibody-drug conjugates.
However, it is important to note that the known biological
activity space of MNPs and derivatives has been influenced by
funding sources, e.g. 5 out of the 8 approved MNP and deri-
vatives drugs (Figure 1) and 19 out of the 22 MNPs and
derivatives in phase I, II, and III of the clinical trials (Figure 2)
are set as anti-cancer drugs. The emphasis on cancer is mainly
due to the fact that the leading funding agency in the U.S. for
MNP and derivatives was for many years the National
Institutes of Health (NIH)/National Cancer Institute (NCI), and
this situation is the same in other countries [4].
Therefore, this corresponds to a higher success rate of
marine compounds, 1 in 3,500 MNPs [4], compared with the
industry average of 1 in 5,000–10,000 compounds [5]. In
recent years, there has been a growing interest in NP-like
scaffolds due to these two factors, on the one hand, the
decreasing number of NMEs in development pipelines and,
on the other hand, the success rate of the marine world.
2. Marine natural product chemical space
NPs remain one of the most productive sources of chemical
inspiration for the development of new drugs. The struc-
tures of more than 440,000 NPs are available from public
databases such as PubChem, REAXYS, ChEMBL, ZINC,
NaprAlert, and Super Natural II [1,8]. From these, approxi-
mately 10% are commercially available compounds [9],
which can be obtained from commercial vendors and public
research institutions to be tested experimentally, e.g. the
ZINC database comprising more than 10,000 purchase NPs
out of 100,000 NPs that are recorded [10].In order to under-
stand the chemical space defined by known and readily
obtainable NPs as well as by individual NP databases, com-
parisons between these chemical spaces and those defined
by drugs and other types of small molecules have been
reported in several works [9,11,12]. Ertl and Schuffenhauer
performed a chemoinformatics analysis of a large collection
of over 130,000 NPs and compared the physicochemical and
structural properties of NPs with those of bioactive and
common synthetic molecules [11]. Although the authors
conclude that there is a clear separation in the structural
space that NPs and synthetic molecules define, they also
found an overlap of the bioactive molecules in both groups
[11]. Chen et al. [9] reported a comprehensive study with
known and readily obtainable NPs from 18 databases, 9
physical libraries, and the Protein Data Bank (PDB). The
authors found that the readily obtainable NPs are highly
diverse and populate regions of chemical space that are of
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high relevance to drug discovery. In the case of PubChem
database and TCM Database@ Taiwan, substantial differ-
ences in the coverage of NP classes and chemical space
by the individual databases are observed, namely the high
proportion of drug-like NPs and chiral NPs, respectively.
Recently, Shang et al. reported a chemoinformatics compar-
ison between the chemical spaces covered by terrestrial and
marine originated NPs and concluded that MNP and terres-
trial NPs (TNPs) may occupy different biologically relevant
chemical spaces [12]. The authors pointed out that MNPs
have lower solubility and are often larger than TNPs and
often contain ester bonds connected to 10-membered rings,
while the scaffolds of the TNPs often have more stable ring
systems and bond types. They also verified that MNPs had
more nitrogen atoms and halogen atoms, especially bro-
mine atoms, and fewer oxygen atoms, suggesting that
MNPs can be synthesized by more diverse biosynthetic
pathways than TNPs [12].
3. Marine natural product drug discovery
In spite of marine invertebrates such as sponge, jellyfish,
anemone, and a rocky coral have been the source of most
bioactive MNPs, with Porifera (sponges) and Cnidaria phyla
being the most prolific, the true origin of most MNPs appears
to be the microorganisms who live with them in a symbiotic
relationship [6]. Almost all of the MNPs approved as drugs or
currently in clinical trials come from bacterial and cyanobac-
terial biosynthetic sources, e.g. brentuximab vedotin (Figure 1,
cyanobacteria Symploca sp.) and salinosporamide A (Figure 2,
actinobacteria Salinispora tropica) [5]. The Ascomycota (Fungi)
and Actinobacteria have been among the four most widely
collected phyla during the last years, along with Porifera and
Cnidaria [6]. Therefore, microbial-derived compounds will
almost certainly dominate the MNP field in the coming years.
The vast majority of currently used antibiotics have been
isolated from terrestrial microbes, accounting for more than
75% of all antibiotics discovered, however antimicrobial
compounds from marine sources have not yet been devel-
oped into clinical trial phases [3,4,13]. As reported above,
there is a vast investment and research in the development
of novel anti-cancer drugs when compared to antibacterial
macromolecules. Wiese et al. reported the analyses of anti-
biotic activity surveys obtained in their lab during the years
2008–2017 and concluded that ca. 50% of the bacterial
isolates revealed antibiotic activity against Gram-positive
(Bacillus subtilis, Staphylococcus lentus) and Gram-negative
strains (Escherichia coli) [3]. The authors underscored the
enormous potential of marine micro-organisms for the pro-
duction of new anti-infective agents with some examples of
MNPs, namely polyketides and cyclic peptides isolated from
bacteria and marine fungi [3], Figure 3. Another interesting
review addressed advances in the discovery of novel anti-
biotics isolated from deep-sea microorganisms, which are
Figure 1. The eight MNPs and derivatives approved drugs, their chemical structures, biological sources, and clinical applications. Adapted from [1] with permission
of MDPI.
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adapted to this extreme environment and therefore have
the potential to produce novel secondary metabolites with
potent biological activities [14]. In Figure 3, a few examples
of deep-see-derived MNPs isolated from actinobacteria and
fungi were also highlighted [15].
The discovery of antibiotics has undoubtedly revolutio-
nized medicine and is considered a turning point in the history
of mankind. However, the most serious consequence of the
use and misuse of antibiotics is the associated development of
resistance against them. The marine environment has proven
to be a very rich source of diverse NPs with relevant activity
against fungal, viral, and parasitic drug-resistant infections
[15,16]. For example, the prenylated indole diketopiperazine
alkaloid neoechinulin B, Figure 4, isolated from a marine-
derived fungus Eurotium rubrum displayed a strong inhibition
against the H1N1 virus in infected MDCK cells and also inhib-
ited several drug-resistant influenza clinical isolates, e.g. resis-
tant against amantadine, oseltamivir phosphate, and
ribavirin [15].
In addition, HIV also exhibits high genetic variability, and thus
develops resistance to existing drugs and escapes host immune
responses elicited by AIDS vaccine candidates. In another exam-
ple, the phenylspirodrimane stachybotrin D, Figure 4, isolated
from the marine sponge-associated fungus Stachybotrys
chartarum, showed inhibition against the HIV-1 virus, as well as
showed similar inhibitory effects on HIV-1 replication of wild type
and several NNRTI-resistant HIV-1 strains [15]. In addition, ben-
gamide A (a seven-membered lactam), Figure 4, isolated from
the marine sponge-associated bacterium Myxococcus virescens,
inhibits HIV replication in vitro and in primary cells with EC50s of
15–32 nM [16]. Bengamide A acts by inhibiting the cellular NF-κB
signaling pathway. The synthetic derivative of bengamide
A (LAF389), Figure 4, was tested as an anti-cancer agent in
phase I of the clinical trials, but the study was terminated due
to cardiovascular and pulmonary toxicities [16].
4. Expert opinion
Although the field of MNP drug discovery has been fully
implemented during the 21st century there are still several
bottlenecks that inhibit the development of drugs from NPs
and particularly MNPs. One of the most important prerequi-
sites is the sustainable supply of NPs through the robust
development of processes using fermentation procedures,
chemical synthesis or genetic methods. For example, the
anti-cancer clinical trial involving cephalostatin 1 (a bis-
steroidal alkaloid) has been hampered because of complica-
tions in the collection of materials [17], Figure 5. Issues
Figure 2. MNPs and derivatives in a) phase III and b) phase II of clinical pipeline.
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related to material harvesting can be overcome for the most
prolific MNPs, the microbial derivative compounds. These
MNPs present several advantages compared to the MNPs
derived from macroorganisms, namely, their direct fermen-
tation, the relative ease of their collection, and the
advanced technologies for the extraction of their genomic
material and their manipulation in heterologous systems, as
well as the application of emerging advanced techniques
[6]. In general, the design and total or semi-synthetic che-
mical synthesis of MNPs derived from macro- or microor-
ganisms has been the approach used to make the
compounds available for clinical trials.
However, even for compounds of moderate complexity,
organic synthesis remains a major challenge. Machine learning
approaches have been successfully used in Computer Aided
Synthesis Planning (CASP) [18,19] – chemical synthesis,
Computer-Assisted Identification of Compounds [1] – derepli-
cation (recognizing and filtering known compounds), and
Computer-Aided Drug Design (CADD) [1] – ligand-based and
structure-based methodologies.
Computer-aided synthetic pathways of isolated NPs such
as a pentacyclic alkaloid, tacamonidine (not yet synthesized
in the laboratory), have recently been reported [19] and
allowed to conclude that computers are currently capable
of designing syntheses important to the everyday practice
of organic synthesis [18,19] after about half a century since
the first project in this field. Several advances have contrib-
uted to the beginning of the success of CASP, e.g. availability
Figure 3. A few examples of antibacterial MNPs and derivatives isolated from marine bacteria and fungi.
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of millions of tabulated reaction examples from United States
Patent and Trademark Office (USPTO), Reaxys, and SciFinder
databases; machine learning techniques (Weisfeller−Lehman
network, Weisfeller−Lehman difference network, graph con-
volutional neural network); establishment of retrosynthetic
rules; predicting reaction conditions (solvent, catalyst, tem-
perature, etc.); and in silico discovery of new reaction types
and mechanisms [18,19]. Therefore, computational methodol-
ogies will be crucial to streamline the identification and
elucidation of MNPs, design and chemical synthesis of
MNPs [18,19], identification and validation of the biological
targets, and prediction of biological activities of MNPs [1].
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